The Alnylam Act Program for AHP Patients [transcript] [audio]

Guest: Dr. Pritesh Gandhi

Presenter: Neal Howard

Guest Bio: Dr. Pritesh Gandhi, PharmD, is Vice President-Medical Affairs at Alnylam Pharmaceuticals, where he leads the execution of key clinical imperatives. Dr. Gandhi joined Alnylam in 2014, coming from Sanofi, where he most recently served as Associate Vice President of Global Medical Affairs. Prior to Sanofi, Dr. Gandhi held leadership positions at Alexion Pharmaceuticals and Millennium Pharmaceuticals (now Takeda Oncology). He received his Doctor of Pharmacy at the Massachusetts College of Pharmacy and Health Sciences and completed a Pharmacy Practice residency at the University of Illinois, Chicago.

Segment Overview: In this health supplier segment Dr. Pritesh Gandhi discusses Alnylam Act, what it is and what it has to offer to those at risk for Acute Hepatic Porphyrias (AHPs). The program was originally for those with hereditary ATTR amyloidoses and has been expanded to include AHPs.

0 Comments

Leave a Reply

You must be logged in to post a comment.